H1B Report
Side-by-side comparison

COGNIZANT TECHNOLOGY SOLUTIONS US CORP vs Main Line HealthCare

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
COGNIZANT TECHNOLOGY SOLUTIONS US CORP
TXRank #2FEIN 13-3924155
Entity B
Main Line HealthCare
PARank #FEIN 23-2359401

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricCOGNIZANT TECHNOLOGY SOLUTIONS US CORPMain Line HealthCare
Total filings128,85252
Certified %96.13%92.31%
Denied %0.28%0.00%
Withdrawn %2.23%7.69%
Cert-withdrawn %1.36%0.00%
Rank#2
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateTXPA

Outcomes — COGNIZANT TECHNOLOGY SOLUTIONS US CORP

DOL case-status mix.

Outcome breakdown: Certified 96.1%, Cert-withdrawn 1.4%, Withdrawn 2.2%, Denied 0.3%
Outcome breakdown
OutcomeShare
Certified96.1%
Cert-withdrawn1.4%
Withdrawn2.2%
Denied0.3%
Certified96.1%
Cert-withdrawn1.4%
Withdrawn2.2%
Denied0.3%

Outcomes — Main Line HealthCare

DOL case-status mix.

Outcome breakdown: Certified 92.3%, Withdrawn 7.7%
Outcome breakdown
OutcomeShare
Certified92.3%
Withdrawn7.7%
Certified92.3%
Withdrawn7.7%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

COGNIZANT TECHNOLOGY SOLUTIONS US CORP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20101,476
FY20112,735
FY20121,772
FY20131,557
FY20142,189
FY20153,112
FY20164,612
FY20172,384
FY201812,460
FY201925,569
FY20203,117
FY202110,079
FY202213,705
FY202315,729
FY202411,437
FY202511,140
FY20265,779
Main Line HealthCare
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102
FY20115
FY20123
FY20130
FY201410
FY20154
FY20161
FY20176
FY20183
FY20192
FY20200
FY20210
FY20222
FY20230
FY20246
FY20253
FY20265

Top 5 occupations — COGNIZANT TECHNOLOGY SOLUTIONS US CORP

Top 5 occupations — Main Line HealthCare

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.